Compounds and compositions for treating neuronal death or neurological dysfunction
First Claim
1. A method for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises administering to the human or animal in need thereof a therapeutically effective amount of a cell necrosis inhibitor and concomitantly or sequentially administering a therapeutically effective amount of lithium or a pharmaceutically acceptable salt thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig'"'"'s disease), spinal muscular atrophy, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.
-
Citations
38 Claims
- 1. A method for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises administering to the human or animal in need thereof a therapeutically effective amount of a cell necrosis inhibitor and concomitantly or sequentially administering a therapeutically effective amount of lithium or a pharmaceutically acceptable salt thereof.
- 9. A pharmaceutical formulation for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises a therapeutically effective amount of a cell necrosis inhibitor and a therapeutically effective amount of lithium or a pharmaceutical acceptable salt thereof.
- 17. A kit for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises a therapeutically effective amount of a cell necrosis inhibitor and a therapeutically effective amount of lithium or a pharmaceutical acceptable salt thereof.
- 25. The compound 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid or a pharmaceutically acceptable salt thereof.
- 27. A method for treating degenerative brain disease, comprising administering to a subject in need thereof a therapeutically effective amount of 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid or a pharmaceutically acceptable salt.
- 29. A method of inhibiting production or aggregation of beta-amyloid, comprising administering to a subject in need thereof a therapeutically effective amount of a 2-hydroxy-alkylamino-benzoic acid derivative represented by the following formula or a pharmaceutically acceptable salt thereof:
- 34. A method for treating or preventing a disease associated with deposition of beta-amyloid, comprising administering to a subject in need thereof a therapeutically effective amount of a 2-hydroxy-alkylamino-benzoic acid derivative represented by the following formula or a pharmaceutically acceptable salt thereof:
Specification